ModeratePolyene systemic antifungal×Glucocorticoids
Updated · Methodology
Mechanism
Amphotericin B causes potassium and magnesium loss, especially at high doses, and corticosteroids can potentiate this hypokalaemia (AmBisome SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Prednisolone itself increases potassium excretion and can cause hypokalaemia, especially with prolonged use of relatively high doses (Paidocort SmPC, AEMPS). For this reason, the prednisolone SmPCs name amphotericin B explicitly: hypokalaemia may increase, with a risk of toxicity (Paidocort SmPC, AEMPS). According to the US amphotericin B label, this hypokalaemia can predispose to cardiac dysfunction (AmBisome label, US Food and Drug Administration, FDA). The documents describe no pharmacokinetic interaction. The metabolic pathways of amphotericin B are unknown, and its documents do not class it among the CYP3A4 inhibitors or inducers that change corticosteroid concentrations (Paidocort and AmBisome SmPCs, AEMPS).
Symptoms
According to the documents, the main risk of the combination is increased hypokalaemia, which can impair cardiac function (Paidocort and AmBisome SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS; AmBisome label, US Food and Drug Administration, FDA). Cases of cardiac enlargement and congestive heart failure have been reported after amphotericin B was combined with hydrocortisone (Orapred ODT label, FDA). Amphotericin B itself very often causes hypokalaemia, nausea and vomiting, as well as fever, chills and rigors during infusion. It can also impair renal function and cause heart rhythm disorders (AmBisome SmPC, AEMPS). Prednisolone causes sodium and water retention, can raise blood pressure and blood glucose, and can mask the signs of infection (Paidocort SmPC, AEMPS).
Management
Except for replacement therapy and emergencies, prednisolone is not used in systemic mycoses, because they may worsen (Paidocort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Amphotericin B is given precisely for severe systemic mycoses (AmBisome SmPC, AEMPS). According to the US label, prednisolone is avoided in systemic fungal infections unless it is needed to control drug reactions. If such an infection develops during long-term prednisolone treatment, stopping prednisolone or reducing its dose is recommended (Orapred ODT label, US Food and Drug Administration, FDA). Hydrocortisone, another corticosteroid, is one of the measures used to prevent and treat amphotericin B infusion-related reactions (AmBisome SmPC, AEMPS). If prednisolone and amphotericin B are combined, serum potassium is monitored (Paidocort SmPC, AEMPS), with close monitoring of serum electrolytes and cardiac function (AmBisome label, FDA). During amphotericin B treatment, potassium, magnesium and renal, hepatic and haematopoietic function are checked periodically, and potassium supplements may be needed for hypokalaemia (AmBisome SmPC, AEMPS). Potassium and renal function are measured before and during amphotericin B treatment, because hyperkalaemia with arrhythmias has been reported in renal impairment and after potassium supplements (AmBisome SmPC, AEMPS). During prolonged treatment with relatively high prednisolone doses, adequate potassium intake is ensured and sodium intake is restricted (Paidocort SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Orapred ODT (prednisolone sodium phosphate) prescribing information (2025)– FDA label, DailyMed setid 1e379543-c4cf-4e72-953b-db15b7f0c2a1, version 12, revised 06/2025, section 7 NSAIDs, including aspirin and salicylates
- AEMPS: Ficha técnica: Prednisolona (nº registro 84003), sección 4.5 (2026)– AEMPS, CIMA, nº registro 84003, revisión 04/2026, sección 4.5
- AEMPS: Ficha técnica AMBISOME LIPOSOMAL 50 MG POLVO PARA DISPERSION PARA PERFUSION (2024)– AEMPS. Ficha técnica AMBISOME LIPOSOMAL 50 MG POLVO PARA DISPERSION PARA PERFUSION (revisión 2024). CIMA, https://cima.aemps.es/cima/dochtml/ft/61117/FT_61117.html
- FDA: AmBisome (amphotericin B liposome) prescribing information (2026)– FDA, DailyMed setid f7be6506-4d20-401e-a0ff-02ad7c33158a (Astellas Pharma US), revised 10/2026 (version 14), Contraindications, Warnings, Precautions (Laboratory Tests, Drug Interactions) and Clinical Studies (infusion-related reactions)